The long-term objective for this continuation application for four years is to elucidate the etiology and pathogenesis of insulin-dependent diabetes mellitus (IDDM). The unique resources of the nationwide Swedish Diabetes Registry, established in 1983, for incident cases of patients developing diabetes mellitus at 15-34 years is utilized in a case- control study with a proposed five year follow-up. In 1992 and 1993, a total of 786 (with a blood sample from 767) patients were recruited. At the time of clinical onset, these patients were classified as IDDM (74%), non-insulin dependent diabetes mellitus (NIDDM) (13%), secondary diabetes (3%) and unclassifiable diabetes (10%). A total of 831 controls donated blood to the study after being selected based on the Swedish civic registration numbers to identify individuals matched for age and sex. This case-control study with follow-up will define genetic, autoimmune and viral antibody markers for the development of IDDM. The primary goal remains to determine whether the same genetic markers known to be associated with IDDM in the 0-14 year olds are also operative in the 15-34 year old group. The 15-34 year olds need to be studied further since: 1) both IDDM and NIDDM as well as unclassifiable diabetes is present, and 2) this age group is particularly suited to test the hypothesis that genetic and antibody markers alone or in combination permit a differential diagnosis of diabetes mellitus already at the time of clinical onset. The five year follow-up is necessary to study the conversion rates from NIDDM/unclassifiable diabetes to IDDM as well as from IDDM to NIDDM. The preliminary results from year One and Two of follow up demonstrate the following: a) decreasing risk of DR3-DQ2 and DR4-DQ8 with increasing age at onset and decreasing protection with age of DQ6; b) increased diagnostic sensitivity with age for GAD65Ab; c) appearance of GAD65Ab and ICA after onset; d) stable C-peptide within the normal range during follow-up and e) that antibodies against certain strains of the Coxsackie B4 subtype are associated with IDDM.
The Specific Aims are therefore: 1) to analyze the large amount of data collected at baseline in the 1992-1993 case-control study; 2) to investigate the association between IDDM and HLA and non-HLA IDDM and NIDDM genetic markers; 3) to determine end-point titers and epitope-specificity of islet cell autoantigen antibodies at onset and during follow-up and 4) to determine antibodies against strains of coxsackie B4 for high infectability for human islets. The data will be analyzed using standard methods for case-control studies including descriptive tabulations, stratified analyses and multiple logistic regression analyses. The investigators state that these studies will help to define pathogenetic mechanisms of IDDM to produce insights to the possibility of prevention or cure of this disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK042654-07
Application #
2701090
Study Section
Epidemiology and Disease Control Subcommittee 2 (EDC)
Program Officer
Harris, Maureen I
Project Start
1991-09-01
Project End
2000-04-30
Budget Start
1998-08-25
Budget End
1999-04-30
Support Year
7
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Ingemansson, Sofie; Vaziri-Sani, Fariba; Lindblad, Ulf et al. (2013) Long-term sustained autoimmune response to beta cell specific zinc transporter (ZnT8, W, R, Q) in young adult patients with preserved beta cell function at diagnosis of diabetes. Autoimmunity 46:50-61
Törn, Carina; Ingemansson, Sofie; Lindblad, Ulf et al. (2011) Excess mortality in middle-aged men with diabetes aged 15-34 years at diagnosis. Acta Diabetol 48:197-202
Jensen, Richard A; Agardh, Elisabet; Lernmark, Ake et al. (2011) HLA genes, islet autoantibodies and residual C-peptide at the clinical onset of type 1 diabetes mellitus and the risk of retinopathy 15 years later. PLoS One 6:e17569
Ramagopalan, S V; Link, J; Byrnes, J K et al. (2009) HLA-DRB1 and month of birth in multiple sclerosis. Neurology 73:2107-11
Jensen, R; Gilliam, L; Torn, C et al. (2007) Islet cell autoantibody levels after the diagnosis of young adult diabetic patients. Diabet Med 24:1221-8
Jensen, Richard A; Gilliam, Lisa K; Torn, Carina et al. (2007) Multiple factors affect the loss of measurable C-peptide over 6 years in newly diagnosed 15- to 35-year-old diabetic subjects. J Diabetes Complications 21:205-13
Padoa, C J; Crowther, N J; Thomas, J W et al. (2005) Epitope analysis of insulin autoantibodies using recombinant Fab. Clin Exp Immunol 140:564-71
Luo, D; Gilliam, L K; Greenbaum, C et al. (2004) Conformation-dependent GAD65 autoantibodies in diabetes. Diabetologia 47:1581-91
Torn, Carina (2003) C-peptide and autoimmune markers in diabetes. Clin Lab 49:1-10
Littorin, B; Nystrom, L; Gullberg, B et al. (2003) Increasing body mass index at diagnosis of diabetes in young adult people during 1983-1999 in the Diabetes Incidence Study in Sweden (DISS). J Intern Med 254:251-6

Showing the most recent 10 out of 70 publications